<DOC>
	<DOCNO>NCT01717768</DOCNO>
	<brief_summary>Low testosterone condition occur body unable produce sufficient quantity testosterone . The medical name low testosterone hypogonadism . Hypogonadism cause many factor . Symptoms include : decrease libido , lack energy mood swing . The goal testosterone replacement therapy return testosterone level normal range relieve symptom . The purpose study evaluate ability TSX-002 , testosterone provide easy swallow capsule , maintain serum ( blood ) testosterone level within normal range hypogonadal men . This determine blood sampling specify time study . The study also intend evaluate tolerability TSX-002 , take orally twice per day 15 day . In addition , study intend determine dose regimen ( ) achieve testosterone level within normal range . Related Outcome Measures report Parts 1 , 2 , 4 . A portion study ( Part 3 ) also assess effect high-calorie , high-fat meal single dose pharmacokinetic exposure TSX-002 . Related outcome measure report Part 3 .</brief_summary>
	<brief_title>Oral Testosterone Treatment Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Hormones , Hormone Substitutes , Hormone Antagonists</mesh_term>
	<criteria>Prior documentation diagnosis hypogonadism evidence screen serum testosterone &lt; 300 ng/dL ( base average 2 morning sample take least 1 week apart ) Men age 18 year body mass index ( BMI ) &lt; 39.0 kg/m2 weigh â‰¥ 55 kg Hemoglobin level screen baseline &gt; 12.5 g/dL Testosterone treatment contraindicate No evidence suspect reversible hypogonadism Willing abstain current treatment hypogonadism accordance approve labeling facilitate appropriate washout period study participation ( nondepot formulation testosterone ) Understands requirement study voluntarily consent participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>hypogonadism</keyword>
	<keyword>Gonadal Disorders</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Testosterone enanthate</keyword>
	<keyword>Testosterone undecanoate</keyword>
	<keyword>Testosterone 17 beta-cypionate</keyword>
	<keyword>Methyltestosterone</keyword>
	<keyword>Androgens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones , Hormone Substitutes , Hormone Antagonists</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Anabolic Agents</keyword>
</DOC>